Key Updates
Global Healthcare Equities has extended its recovery trajectory, advancing 2.94% to $31.19 since the December report. The fund maintains positive momentum across all timeframes, with YTD gains of 3.72% and six-month returns of 13.54%. The healthcare sector continues to demonstrate relative value compared to broader markets, with forward P/E multiples trading at a 12% premium to 10-year averages versus the S&P 500's 19% premium. Recent news flow highlights continued innovation in medical technology, regulatory approvals for GLP-1 obesity treatments, and strategic M&A activity in healthcare infrastructure, supporting the sector's growth narrative.
Current Trend
The fund exhibits strong positive momentum with consistent gains across all measured periods: +1.53% (1d), +3.48% (5d), +4.98% (1m), and +13.54% (6m). The YTD performance of +3.72% establishes a solid foundation for 2026, building on the recovery that began in mid-2025. The current price of $31.19 represents a new high for the reporting period, surpassing the previous $30.30 level from December. Technical momentum remains constructive with no signs of exhaustion, as each pullback has been met with renewed buying interest. The fund has successfully maintained its uptrend from the July 2025 low of $27.56, representing a cumulative gain of 13.2% over this period.
Investment Thesis
The investment thesis centers on healthcare sector's attractive relative valuation combined with sustained innovation across therapeutics, medical technology, and digital health infrastructure. The sector trades at an 18.2 forward P/E versus the S&P 500's 22.4, offering a compelling entry point for long-term capital appreciation. Key structural drivers include the obesity drug market expansion with oral GLP-1 formulations, medical device innovation with regulatory approvals opening new markets, and consolidation in healthcare infrastructure creating efficiency gains. The sector benefits from demographic tailwinds, non-cyclical demand characteristics, and a robust M&A environment where smaller biotech firms are achieving profitability and attracting strategic interest. International expansion opportunities, particularly in European and emerging markets, provide additional growth vectors for global healthcare companies.
Thesis Status
The investment thesis remains intact and has strengthened since the December report. The relative valuation argument has been reinforced by sector-specific analysis showing healthcare's forward P/E at 18.2 versus S&P 500's 22.4, validating the attractive entry point. Innovation catalysts continue to materialize, with Novo Nordisk's oral obesity drug approval representing a significant advancement in the blockbuster GLP-1 category. The M&A thesis is supported by TPG's £1.2-1.4 billion negotiations for UnitedHealth's Optum UK and EssilorLuxottica's acquisition of Signifeye. Market positioning by institutional investors, including Wall Street forecasters increasingly favoring international stocks for 2026, aligns with the fund's global healthcare exposure strategy.
Key Drivers
The obesity drug market continues to expand with Novo Nordisk receiving U.S. approval for oral Wegovy, driving a 7.6% stock surge, while Eli Lilly prepares to launch competing oral medication orforglipron in Q1 with projected $3.3 billion full-year sales. Medical technology innovation advances with Sky Labs securing CE-MDR certification for its CART PLATFORM, accessing a European market of 520 million people after deployment in 1,700 Korean hospitals. Strategic M&A activity accelerates as TPG negotiates to acquire UnitedHealth's Optum UK for £1.2-1.4 billion and Healthcare Holding Schweiz acquires majority stake in Medddbase International, handling 500,000 annual product shipments. The JPMorgan Healthcare Conference scheduled for next week is expected to provide updates on acquisitions, partnerships, and Q4 earnings preannouncements from major healthcare companies. Institutional capital allocation shifts toward international equities, with Morningstar releasing top-rated international-stock funds for 2026 and Harris Oakmark launching international and global value ETFs.
Technical Analysis
The fund maintains a well-defined uptrend with the current price of $31.19 establishing a new cycle high. The six-month gain of 13.54% demonstrates sustained momentum, while the YTD advance of 3.72% provides a solid foundation for continued appreciation. Near-term support is established at the $30.30 level from the previous report, with secondary support at the one-month low around $29.70 (implied by the +4.98% monthly gain). The fund has successfully navigated through multiple resistance levels, with each consolidation phase resolving to the upside. Short-term momentum indicators remain positive, as evidenced by the accelerating gains over progressively shorter timeframes (1d: +1.53%, 5d: +3.48%). The absence of overbought conditions or momentum divergences suggests the uptrend has room to extend. Volume and participation metrics are not provided, but the consistent price appreciation across multiple timeframes indicates broad-based buying interest.
Bull Case
- Healthcare sector trades at forward P/E of 18.2 versus S&P 500's 22.4, representing a 12% premium to 10-year average compared to broader market's 19% premium, offering compelling relative value for capital appreciation with lower valuation risk than technology-heavy indices.
- Novo Nordisk's U.S. approval for oral Wegovy marks first oral medication in blockbuster GLP-1 class with sales beginning early January, while Eli Lilly's orforglipron launch in Q1 projects $3.3 billion full-year sales, expanding addressable market beyond injectable formulations.
- Active M&A environment with TPG's £1.2-1.4 billion Optum UK acquisition and six portfolio companies acquired in 2024 demonstrates strategic buyer appetite and validates private market premiums to public valuations.
- Medical technology innovation with Sky Labs' CE-MDR certification accessing 520 million European consumers and Healthcare Holding Schweiz creating enhanced gateway for North American and Asian suppliers entering European market expands addressable markets for portfolio companies.
- Wall Street forecasters increasingly view international stocks as promising for 2026 with non-US stocks representing 37% of global market capitalization, positioning global healthcare funds to benefit from capital reallocation away from concentrated US technology exposure.
Bear Case
- Healthcare sector underperformed with Eli Lilly declining 1-4% as pharmaceutical stocks fell following Novo Nordisk's oral GLP-1 launch, indicating competitive intensity in obesity drug market may compress margins and market share for incumbent players.
- UnitedHealth divesting Optum UK just two years after £1.24 billion acquisition suggests strategic challenges in healthcare infrastructure businesses and potential for portfolio companies to face integration difficulties or regulatory pressures requiring asset sales at unfavorable valuations.
- Concentrated portfolio with 69% in top 10 holdings and Eli Lilly at 19.2% weighting creates significant single-stock risk, where adverse developments in largest positions could disproportionately impact fund performance despite broader sector strength.
- Growing ETF product launches including Dimensional's actively-managed UCITS ETFs and Harris Oakmark's international value ETFs intensify competition for assets under management, potentially compressing fee structures and forcing active managers to take on greater risk to differentiate performance.
- Energy and financial sectors leading market gains while healthcare underperforms indicates sector rotation away from defensive healthcare positioning, with cyclical stocks like autos and banks lagging defensive telecoms and financials suggesting macro uncertainty that could reverse if economic conditions deteriorate.